AI assistant
Sending…
Lyra Therapeutics, Inc. — Director's Dealing 2021
Feb 10, 2021
35183_dirs_2021-02-10_01627700-128b-4b7e-a4f2-217c55d2f064.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lyra Therapeutics, Inc. (LYRA)
CIK: 0001327273
Period of Report: 2021-02-08
Reporting Person: Noyes Corinne (See Remarks)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-08 | Stock Option | $10.63 | A | 30000 | Acquired | 2031-02-07 | Common Stock (30000) | Direct |
Footnotes
F1: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following February 8, 2021.
More from Lyra Therapeutics, Inc.
Delisting Announcement
2026
Apr 20
Regulatory Filings
2026
Apr 17
Regulatory Filings
2026
Apr 10
Annual Report
2026
Mar 31
Regulatory Filings
2026
Mar 27
Regulatory Filings
2026
Mar 27
Regulatory Filings
2026
Mar 27
Regulatory Filings
2026
Feb 27
Regulatory Filings
2026
Feb 6
Major Shareholding Notification
2026
Jan 20